Lazard Asset Management
BBIO icon

Lazard Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Lazard Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.16M Buy
56,000
+32,000
+133% +$2.32M 0.01% 609
2025
Q4 		$1.84M Buy
+24,000
New +$1.58M ﹤0.01% 907

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lazard Asset Management's BBIO Position: Q1 2026 in Review

Lazard Asset Management increased its BridgeBio Pharma (BBIO) stake by 498% in Q1 2026, buying an estimated $448K and bringing the position to 7,421 shares worth $551K. The position accounts for ﹤0.01% of the portfolio, ranked #1350.

Lazard Asset Management first reported a position in BBIO in Q4 2020 and has held it in 13 quarters since. The position peaked at $990K in Q3 2022. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Lazard Asset Management held 7,421 shares of BridgeBio Pharma worth $551K as of Q1 2026.
  • Lazard Asset Management bought 6,181 BridgeBio Pharma shares in Q1 2026, an estimated $448K.
  • BridgeBio Pharma made up ﹤0.01% of Lazard Asset Management's portfolio in Q1 2026, its #1350 holding.
  • Lazard Asset Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 13 quarters since.
  • Lazard Asset Management's BridgeBio Pharma position peaked at $990K in Q3 2022.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.